Literature DB >> 11979555

Detailed genomic mapping and expression analyses of 12p amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for amplification.

Markus Heidenblad1, Tord Jonson, Eija H Mahlamäki, Ludmila Gorunova, Ritva Karhu, Bertil Johansson, Mattias Höglund.   

Abstract

Previous cytogenetic and comparative genomic hybridization (CGH) analyses have shown that the gain of chromosome arm 12p is frequent in pancreatic carcinomas. We investigated 15 pancreatic carcinoma cell lines using CGH, fluorescence in situ hybridization (FISH), and semiquantitative polymerase chain reaction (PCR) to characterize 12p amplifications in detail. The CGH analysis revealed gains of 12p in four of the cell lines and local amplification within 12p11-12 in six cell lines. By FISH analysis, using precisely mapped YAC clones, the commonly amplified region was found to be approximately 5 Mb. The amplified segment extended from YAC 753f12, covering the KRAS2 locus, to YAC 891f1, close to the centromere. A semiquantitative PCR methodology was used to estimate genomic copy numbers of 14 precisely mapped expressed sequence tags (ESTs) and sequence-tagged sites, located within this interval. The level of amplification ranged from two- to 12-fold. The produced gene copy profiles revealed a 3.5-Mb segment with various local amplifications. This region includes KRAS2 and ranges from D12S1617 to sts-N38796. Two of the cell lines (primary and metastatic tumor from the same patient) showed amplification peaks within the distal region of this segment, two had peaks within the proximal region, one showed subpeaks in both regions, and one displayed amplification of the entire region. Chromosome segment-specific cDNA array analysis of 29 expressed sequences within the whole interval between D12S1617 and sts-N38796 indicated overexpression of four ESTs, two corresponding to DEC2 and PPFIBP1, and two to ESTs with unknown function. Expression analysis of these and of KRAS2 showed specific overexpression in the six cell lines with local 12p amplifications. These findings indicate two target regions within the 3.5-Mb segment in 12p11-12, one proximal including PPFIBP1, and one distal including KRAS2. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979555     DOI: 10.1002/gcc.10063

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.

Authors:  Saravana P Selvanathan; Garrett T Graham; Hayriye V Erkizan; Uta Dirksen; Thanemozhi G Natarajan; Aleksandra Dakic; Songtao Yu; Xuefeng Liu; Michelle T Paulsen; Mats E Ljungman; Cathy H Wu; Elizabeth R Lawlor; Aykut Üren; Jeffrey A Toretsky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

2.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Authors:  Murali D Bashyam; Ryan Bair; Young H Kim; Pei Wang; Tina Hernandez-Boussard; Collins A Karikari; Robert Tibshirani; Anirban Maitra; Jonathan R Pollack
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

3.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

4.  KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.

Authors:  Alyssa M Krasinskas; A James Moser; Burcu Saka; N Volkan Adsay; Simion I Chiosea
Journal:  Mod Pathol       Date:  2013-04-19       Impact factor: 7.842

Review 5.  New insights into the pathology and molecular biology of human germ cell tumors.

Authors:  Friedemann Honecker; J Wolter Oosterhuis; Frank Mayer; Jörg Thomas Hartmann; Carsten Bokemeyer; Leendert H J Looijenga
Journal:  World J Urol       Date:  2004-03-20       Impact factor: 4.226

6.  Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

Authors:  Sebastian Mueller; Thomas Engleitner; Roman Maresch; Magdalena Zukowska; Sebastian Lange; Thorsten Kaltenbacher; Björn Konukiewitz; Rupert Öllinger; Maximilian Zwiebel; Alex Strong; Hsi-Yu Yen; Ruby Banerjee; Sandra Louzada; Beiyuan Fu; Barbara Seidler; Juliana Götzfried; Kathleen Schuck; Zonera Hassan; Andreas Arbeiter; Nina Schönhuber; Sabine Klein; Christian Veltkamp; Mathias Friedrich; Lena Rad; Maxim Barenboim; Christoph Ziegenhain; Julia Hess; Oliver M Dovey; Stefan Eser; Swati Parekh; Fernando Constantino-Casas; Jorge de la Rosa; Marta I Sierra; Mario Fraga; Julia Mayerle; Günter Klöppel; Juan Cadiñanos; Pentao Liu; George Vassiliou; Wilko Weichert; Katja Steiger; Wolfgang Enard; Roland M Schmid; Fengtang Yang; Kristian Unger; Günter Schneider; Ignacio Varela; Allan Bradley; Dieter Saur; Roland Rad
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

7.  The decisive role of molecular pathology in presumed somatic metastases of type II testicular germ cell tumors: report of 2 cases.

Authors:  Mariëtte E G Kranendonk; Wenzel M Hackeng; G Johan A Offerhaus; Folkert H M Morsink; Geertruida N Jonges; Gerard Groenewegen; Pieter-Jaap Krijtenburg; Heinz-Josef Klümpen; Wendy W J de Leng; Leendert H J Looijenga; Lodewijk A A Brosens
Journal:  Diagn Pathol       Date:  2020-07-25       Impact factor: 2.644

8.  Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.

Authors:  Markus Heidenblad; David Lindgren; Tord Jonson; Fredrik Liedberg; Srinivas Veerla; Gunilla Chebil; Sigurdur Gudjonsson; Ake Borg; Wiking Månsson; Mattias Höglund
Journal:  BMC Med Genomics       Date:  2008-01-31       Impact factor: 3.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.